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Reactive oxygen speciesAbstract Background and purpose: The 6th edition of International Diabetes Federation, 2014
shows an estimate of 387 million people with Type 2 diabetes mellitus (T2DM) worldwide, expected
to rise to 592 million by 2035. T2DM is a metabolic disorder, one of the reasons being oxidative
stress due to impairment in antioxidant enzymes. It leads to several complications such as micro
and macrovascular diseases. Cyclooxygenase1 (COX1) enzyme is the rate limiting factor for the
arachidonic pathway leading to vascular wall contraction with angiotensin II occurring in heart dis-
eases resulting from T2DM. COX1 determines 6-Keto Prostaglandin F1a (6-k-PGF1a) level, plays a
major role in vasodilation and restricts macrophage platelet aggregation. The aim of the present
study was to compare the COX1 expression and level of reactive oxygen species (ROS) in T2DM
patients and controls at different time periods in human macrophages in order to ﬁnd a biomarker
or drug target.
Subjects and methods: The study subjects consisted of 100 individuals, 50 each from T2DM
patients and healthy sex/age matched controls. Cell proliferation by 3-(4,5-dimethylthiazol-2-yl)-2
,5-diphenyltetrazolium bromide (MTT) assay and ROS measurement by 20,70-dichloroﬂuorescein
diacetate (DCFDA) staining were performed at different time periods (24, 48, 72 h). COX1
mRNA expression was checked by relative quantiﬁcation method after real-time polymerase chain
reaction (RT-PCR).
Results: The MTT assay showed that cell viability was signiﬁcantly higher at 48 h (P< 0.05).
ROS production was found to be lowest at 24 h by DCFDA staining. ROS levels were raised in
T2DM patients as compared to controls. The quantitative RT-PCR analysis showed that the
COX1 expression was higher in T2DM patients as compared to healthy controls although not
signiﬁcant (P> 0.05).MCSF,
species;
42 S. Verma et al.Conclusion: Although COX1 is known to be a ‘‘housekeeping’’ gene, our study showed that
its expression can be correlated with the disease condition and be used as a marker. However, fur-
ther studies are required in more number of samples from other ethnic populations to conﬁrm the
ﬁndings.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diabetes is a metabolic disorder characterized by chronic
hyperglycemia, leading to many complications viz. atheroscle-
rosis, coronary heart disease, micro and macrovascular dis-
eases. The 6th edition of International Diabetes Federation
showed that prevalence of diabetes was 8.3% in 2013 and is
expected to rise to 10.1% in 2035. The estimates in India
showed 65.1 million diabetics in 2013 which has been predicted
to reach 109 million till 2035 [1]. Susceptibility to diabetes
depends on age, environmental factors and genetic makeup.
Cyclooxygenase (COX) has several isoforms, COX1 and
COX2 being the two major ones. They show 60% homology
but have different localizations [2–3]. COX1 is found in the
endoplasmic reticulum whereas COX2 is found in the nuclear
envelope [4].
COX1 is expressed constitutively in bronchial epithelial,
smooth muscles, gastric mucosa and monocyte and any change
in its level affects various organs viz. the kidney, stomach and
central nervous system [2,4–6]. It is a rate limiting enzyme in
the arachidonic to prostanoid pathway [5,7,8]. COX1 is
expressed in inﬂammatory cells and restricts the macrophage
platelet aggregation [9]. It also leads to vasoconstriction and
vasodilation [10] with the help of angiotensin II (angII) derived
reactive oxygen species (ROS) [11]. Sometimes in the case of
high ROS production, it exerts vascular damage by initiating
the redox signaling pathway [12]. COX1 gene is 22 kb in size
with 11 exons located on chromosome 9 [5]. The expression
of COX1 gene is induced by proinﬂammatory stimuli viz
growth factors, cytokines and mitogens in various cells [13].
However, some workers suggested that it is unaffected by
cytokines and inﬂammatory molecules [9]. The COX1 expres-
sion level increases at the time of onset of diabetes [7] and is
associated with excess cardiovascular morbidity. There has
been a constant search for biomarkers and drug targets for
T2DM and its complications. The aim of the present study
was to establish a system for gene expression studies and
search for a T2DM marker in north Indian population.
Therefore, an attempt was made to determine the COX1
expression and levels of reactive oxygen species (ROS) in
T2DM patients and controls at different time periods in
human macrophages.2. Subjects and methods
2.1. Participants
Blood samples were collected from T2DM patients (n= 50)
and control subjects (n= 50) at Balarampur Hospital,
Lucknow, India under the supervision of expert clinicians.
The study was approved by the Institutional Ethics
Committee and written informed consent was taken from allsubjects. The work has been carried out in accordance with
the Code of Ethics of the world Medical association
(Declaration of Helsinki) for experiments in humans.
Controls showed a normal oral glucose tolerance test and no
family history of coronary artery disease or other metabolic
disorders, while diabetic cases showed fasting glucose
concentration of P126 mg/dl or 2-h glucose concentration of
P200 mg/dl after a 75-g oral glucose tolerance test.
Clinical details of patients and controls were recorded and
diabetes-associated complications were reviewed [14].
2.2. Culture of macrophages
Mononuclear cells were isolated by centrifugation of EDTA-
blood at 1200 rpm by Histopaque density gradient separation
using HiSep 1077 (HiMedia) at room temperature. The
mononuclear cell suspension (0.5 ml) was transferred to 6 well
culture plates containing macrophage serum free (MSF) media
(Thermo Fisher, USA), colony stimulating factor (MCSF,
100 ng/ml), 1.0% media supplement, insulin transferin sele-
nium A (ITS-A) and antibiotics. The plates were incubated
in a CO2 incubator (37 C; 5.0% CO2) for cell proliferation
[15].
2.3. MTT assay
Cell viability was performed using tetrazolium dye 3-(4,5-dime
thylthiazol-2-yl)-2-5-diphenyltetrazolium bromide (MTT)
assay at 24, 48, and 72 h and optical density was measured
at 490 nm using Enzyme Linked Immunosorbent Assay
(ELISA) microplate reader (Biorad, USA).
2.4. ROS measurement
Reactive oxygen species (ROS) generation in monocyte cell
derived macrophages were measured by ﬂuorescent 20,70-dichl
oroﬂuorescein diacetate (DCFDA) staining with some modiﬁ-
cations at 24, 48, and 72 h [16]. Images were taken in an
inverted ﬂuorescent microscope (Nikon ECLIPSE Ti-S,
Japan).
2.5. Gene expression
RNA was isolated from monocyte-derived macrophages with
the help of RNeasy kit (Qiagen, The Netherlands).
Complimentary DNA (cDNA) was synthesized by commer-
cially available SuperScript VILO cDNA synthesis kit
(Biosciences, USA) as per manufacturers protocol.
Quantitative real-time PCR (RT-PCR) with SYBR green I
master mix was performed in a Light Cycler 480 real-time
PCR machine (Roche, Germany) using speciﬁc primers for
COX1 and the housekeeping gene, GAPDH as internal
Figure 1 Bar diagram showing cell viability (A490) of human
macrophages at 24, 48, and 72 h.
Figure 2 Human macrophages stained with DCFDA showing
levels of ROS (a) normal and (b) T2DM cases.
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further checked by OligoAnalyser (ver. online) (Table 1).
Relative quantiﬁcation methodology was used to study the
expression levels [15].
2.6. Statistical analysis
Students’ t-test (two-tailed) was used for cell viability analysis
and evaluation of variation in expression levels between controls
and T2DM cases using Prism software (V 5.0). Difference
between variables was considered signiﬁcant at P< 0.05.
3. Results
Cell viability analysis by MTT assay clearly indicated that cells
at 48 h (h) were more viable than those at 24 and 72 h. Student
paired t-test showed that cell viability decreased signiﬁcantly at
48 and 72 h (P< 0.0034; 0.0085 respectively) (Fig. 1).
DCFDA staining at different time periods showed that
ROS production was lower at 24 h in comparison to 48 and
72 h in both normal and T2DM subjects. ROS production
increased with time and when the levels were compared
between normal and T2DM subjects, the difference was clearly
visible as shown in Fig. 2. The cultured macrophages from
T2DM individuals appeared brightly stained showing signiﬁ-
cant ROS production.
The COX1 mRNA expression was higher in cells grown for
48 h in comparison to other time periods. The COX1 expres-
sion was higher in diabetic samples as observed in 24 and
48 h (Fig. 3). However, the difference in mRNA expression
levels in the normal and T2DM subjects was not signiﬁcant.
4. Discussion
T2DM is a metabolic syndrome with increased glucose levels,
abdominal obesity, high cholesterol and blood pressure. These
conditions create stress in the biological system due to inﬂam-
mation and ROS generation. It was suggested that poor glyce-
mic control in subjects increases ROS production which leads
to stimulation of the redox pathway [7,17]. ROS is managed by
enzymatic and non-enzymatic mechanisms. Different antioxi-
dant enzymes viz. glutathione S-transferase (GST), superoxide
dismutase (SOD), catalase (CAT) and COX maintain
homeostasis in the cell [18]. As mentioned earlier, COX are
key regulators in the conversion of arachidonic acid into pros-
tanoids which mediate inﬂammation, immunomodulation,
apoptosis and blood ﬂow [19].
As reported earlier, our study also showed the expression of
COX1 in monocytes isolated from peripheral cells [4]. In this
study, we found that ROS generation increased with time
and was higher in T2DM subjects as compared to controls.Table 1 Speciﬁc primers, PCR conditions and amplicon sizes of CO
Gene Primers (50–30) A
COX1 F0 AAGGAGATGGCAGCAGAGTT 5
COX1 R0 GTGGCCGTCTTGACAATGTT
GAPDH F0 TCATCCCTGAGCTGAACGG 6
GAPDH R0 GTCAAAGGTGGAGGAGTGGGWe found highest ROS generation at 72 h and lowest at
24 h. Our results also indicated that COX1 expression was
upregulated in T2DM cases as compared to controls but the
change was not signiﬁcant. The respective ROS and COX1
levels at different time periods showed that ROS production
is directly proportional to COX1 levels (Fig. 3).
There are controversial views regarding COX1 expression
such as no expression was observed in rat alveolar macro-
phages while a marked over expression was reported in mice
and human macrophages [20–23]. However, there are several
studies which suggest that COX1 expression can be modulated
differentially by different cells under various conditionsX1 and GAPDH genes.
nnealing temp (C) Cycles Amplicon size (bp)
7 55 236
1 55 230
Figure 3 Bar diagram showing COX1-mRNA expression levels
in (n) normal and (d) T2DM cases at different time periods.
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expression goes down with glucose concentration under condi-
tions of increased ROS, whereas, others suggested that ROS
upregulates the COX1 expression [7,19].
Unlike the study suggesting COX1 down regulation in the
presence of ROS [7], an increase in COX1 expression was
observed in the north Indian diabetic patients. However, the
increase was not signiﬁcant when compared to controls. Our
study also supported the report of Kottireddy et al. [27].
These ﬁndings suggested that there are several factors and dif-
ferent genes in various pathways which may be inﬂuencing the
expression of COX1. However, further studies are required in
more number of samples in order to establish a correlation
between COX1 expression and T2DM.Disclosure statement
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